Kevin F. Boehnke (
Saurav Gangopadhyay is a consultant at Deloitte in Chicago, Illinois.
Health Aff (Millwood). 2019 Feb;38(2):295-302. doi: 10.1377/hlthaff.2018.05266.
The evidence for cannabis's treatment efficacy across different conditions varies widely, and comprehensive data on the conditions for which people use cannabis are lacking. We analyzed state registry data to provide nationwide estimates characterizing the qualifying conditions for which patients are licensed to use cannabis medically. We also compared the prevalence of medical cannabis qualifying conditions to recent evidence from the National Academies of Sciences, Engineering, and Medicine report on cannabis's efficacy in treating each condition. Twenty states and the District of Columbia had available registry data on patient numbers, and fifteen states had data on patient-reported qualifying conditions. Chronic pain is currently and historically the most common qualifying condition reported by medical cannabis patients (64.9 percent in 2016). Of all patient-reported qualifying conditions, 85.5 percent had either substantial or conclusive evidence of therapeutic efficacy. As medical cannabis use continues to increase, creating a nationwide patient registry would facilitate better understanding of trends in use and of its potential effectiveness.
大麻在不同病症中的治疗效果的证据差异很大，并且缺乏关于人们使用大麻的病症的综合数据。我们分析了州登记数据，提供了全国性的估计数据，描述了患者获得医用大麻许可的合格病症。我们还将医用大麻合格病症的流行率与最近美国国家科学院、工程院和医学院关于大麻治疗每种病症的功效的报告中的证据进行了比较。20 个州和哥伦比亚特区有关于患者数量的登记数据，15 个州有关于患者报告的合格病症的数据。慢性疼痛是目前和历史上最常见的医用大麻患者报告的合格病症（2016 年为 64.9%）。在所有患者报告的合格病症中，85.5%有充分或确凿的治疗效果证据。随着医用大麻的使用持续增加，建立一个全国性的患者登记系统将有助于更好地了解使用趋势及其潜在的有效性。
